On May 1, 2026, Japan will officially implement the new medical device standard JIS T 0112:2026, introducing for the first time a mandatory annual attenuation limit requirement for zero-point drift in medical pressure sensors. This standard will directly affect Chinese medical device export enterprises targeting the Japanese market, especially in supporting fields for key equipment such as blood pressure monitoring and respiratory support, where the compliance threshold has risen significantly.

Event Overview

Starting from May 1, 2026, Japan’s new medical device standard JIS T 0112:2026 will take full effect. For the first time, this standard sets a mandatory technical limit of ‘zero-point drift annual attenuation rate ≤0.1%FS/year’ for medical pressure sensors (including models used in clinical scenarios such as blood pressure monitoring and ventilators), and explicitly requires manufacturers to submit compliant accelerated aging test reports. This standard has been officially incorporated into the import review checklist of Japan’s Pharmaceuticals and Medical Devices Agency (PMDA); enterprises that fail to complete the corresponding verification will be unable to obtain Japanese medical device certification (JPAL), and will consequently lose eligibility to supply Japanese hospitals and OEM customers.

Which Market Segments Will Be Affected

Direct trading enterprises: As the main entities exporting to Japan, their product registration and market access will be directly restricted. JPAL certification is a legal prerequisite for entering Japan’s medical procurement system. Failure to meet the zero-point drift verification requirements of JIS T 0112:2026 will result in inability to deliver signed orders, rejection of new bids, suspension of existing channel partnerships, and a remediation cycle that usually requires 6–12 months.

Raw material procurement enterprises: The long-term stability parameters of core sensitive components in pressure sensors (such as silicon piezoresistive chips, ceramic substrates, and packaging gel compounds) were previously mostly controlled according to IEC 60601 or general industrial standards, without systematically covering annual-scale zero-point attenuation. The new regulation is forcing upstream material suppliers to provide more detailed aging data packages (such as original curves from 1000-hour accelerated tests under coupled temperature-humidity-bias stress), otherwise downstream manufacturers will be unable to complete whole-device verification.

Processing and manufacturing enterprises: This involves sensor assembly, calibration, aging screening, and factory testing processes. The new requirements have substantially raised the precision of production process control—for example, calibration environment temperature control must be better than ±0.3℃, aging tests must cover at least two temperature gradients (such as 40℃/85%RH and 60℃/95%RH), and fully traceable data throughout the process must be retained. Some small and medium-sized contract manufacturers, lacking accelerated aging test equipment and data modeling capabilities, are facing pressure to upgrade processes or outsource verification.

Supply chain service enterprises: These include third-party testing laboratories, certification consulting institutions, and compliance data management platforms. Currently, there are fewer than 5 domestic laboratories capable of full-item verification under JIS T 0112:2026 (including review of extrapolation models for zero-point drift annual attenuation), and service scheduling has already been extended to Q3 2026; meanwhile, the JPAL application pathway has added a new step of “aging data reliability assessment,” imposing higher requirements on service providers’ technical interpretation and cross-standard comparison capabilities.

Key Focus Areas and Response Measures for Relevant Enterprises or Practitioners

Immediately start baseline testing for zero-point drift of existing products

Conduct ≥3 months of measured tracking based on current batch samples (not just a one-time calibration), establish an initial drift rate database, identify whether there is a systematic out-of-tolerance trend (for example, accelerated attenuation caused by deviation in the thermal expansion coefficient of packaging gel in a certain batch), and provide a basis for subsequent accelerated test design.

Prudently assess the rationality of accelerated aging test plans

JIS T 0112:2026 does not prescribe a unified acceleration model, but PMDA review focuses on verification of the applicability of the Arrhenius model. Enterprises must prove that the selected temperature/humidity stress conditions are physically relevant to actual clinical usage scenarios, and avoid simply applying high-stress solutions from consumer electronics categories (such as 120℃ baking), otherwise the test report may be rejected.

Synchronously update technical documentation and quality system documents

It is necessary to add a “long-term zero-point stability control procedure” to the quality manual, supplement drift failure mode analysis (FMEA) in the Design History File (DHF), and add a dual-signoff step for zero-point calibration before and after aging in production records—JPAL on-site inspections have already listed such process evidence as a high-frequency audit item.

Prioritize connection with localized service institutions qualified for PMDA filing

As of April 2026, only 2 testing institutions in China are recognized by PMDA to conduct verification for zero-point drift items under JIS T 0112:2026. Enterprises should avoid selecting service providers that only have CNAS qualifications but no PMDA filing, so as to prevent test reports from not being accepted and causing repeated investment.

Editorial Viewpoint / Industry Observation

Observably, this standard shift reflects Japan’s broader regulatory pivot from ‘safety-first’ to ‘longitudinal reliability-first’ in critical-care device components — especially where sensor drift directly impacts clinical decision thresholds (e.g., invasive blood pressure monitoring). Analysis shows the ≤0.1%FS/year limit aligns closely with top-tier European OEM specifications but exceeds current common practice among mid-tier Chinese suppliers by ~2–3× in typical field performance. From an industry perspective, it is not merely a compliance hurdle but a signal of tightening convergence between Japanese and EU MDR expectations on component-level lifetime validation. What matters more now is not just passing a test, but embedding drift-awareness across R&D, procurement, and quality systems.

Conclusion

The implementation of JIS T 0112:2026 marks the shift in medical sensor regulation from static performance verification to dynamic reliability governance. For China’s industry, its significance lies not only in overcoming the barrier to entry into a single market, but more importantly in driving the entire pressure sensor industrial chain to establish a quality paradigm centered on “stability over the time dimension.” Rationally speaking, short-term pain is unavoidable, but enterprises that take the lead in completing technical adaptation may use this opportunity to reshape their value positioning in the high-end medical supply chain across the Asia-Pacific region.

Information Source Notes

Announcement of JIS T 0112:2026 by the Japanese Industrial Standards Committee (JISC) (released in March 2026); Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), “2026 Update to Key Points for Medical Device Import Review” (effective April 2026); Japan’s Ministry of Economy, Trade and Industry, “Operational Guidelines for Linking JIS Standards and JPAL Certification (V2.1)”. Note: Whether PMDA will subsequently extend this limit to related standards such as JIS T 0111 (medical flow sensors) remains subject to continuous observation.